

PRESS  
RELEASE



## Dassault Systèmes and Ipsen sign collaborative agreement to develop innovative programs to support Ipsen's drug discovery

### Leveraging its instrumental contribution to the BioIntelligence consortium, Ipsen has decided to deploy the 3DEXPERIENCE platform

Paris (France), April 5, 2016 — [Dassault Systèmes](#) (Euronext Paris: #13065, DSY.PA), the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions, and Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical group, today announced their collaboration for innovative programs using the 3DEXPERIENCE platform.

Ipsen has selected the "[Designed to Cure](#)" industry solution experience to accelerate its research and development (R&D) transformation and discovery of new therapeutic solutions. The platform offers data integration, modeling and simulation capabilities to gain a more comprehensive view of the dysregulations linked to diseases as well as improves and shortens the identification of higher quality drug candidates. The project also aims to optimize the R&D processes of Ipsen's multi-disciplinary teams located in the heart of the leading biotechnological and life sciences hubs in France, the U.K. and the U.S., as well as those of its worldwide network of drug development partners including world-class scientists, Biotechs, clinical research organizations, and other stakeholders.

*"After more than five years of partnering with Dassault Systèmes on the BioIntelligence, we are pleased to achieve a key step in our collaboration with the deployment of this set of cutting edge innovative tools,"* said **Claude Bertrand, Executive Vice President, R&D and Chief Scientific Officer, Ipsen.** *"Ipsen as a key scientific partner has 'open innovation' in its DNA and this new collaborative and innovative digital platform will support Ipsen's commitment to achieve therapeutic breakthroughs in patient care."*

*"The virtual world offers the pharmaceutical industry opportunities to reinvent collaboration, connect unrelated disciplines and simulate human biological complex phenomena like never before,"* said **Jean Colombel, Vice President, Life Sciences Industry, Dassault Systèmes.** *"Our partnership with Ipsen on the adoption of the 3DEXPERIENCE platform furthers the promise of the 3D experience approach by bridging life sciences disciplines and delivering innovative patient experiences."*



### **About Dassault Systèmes**

Dassault Systèmes, the 3DEXPERIENCE Company, provides business and people with virtual universes to imagine sustainable innovations. Its world-leading solutions transform the way products are designed, produced, and supported. Dassault Systèmes' collaborative solutions foster social innovation, expanding possibilities for the virtual world to improve the real world. The group brings value to over 210,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit [www.3ds.com](http://www.3ds.com).

*3DEXPERIENCE, the Compass logo and the 3DS logo, CATIA, SOLIDWORKS, ENOVIA, DELMIA, SIMULIA, GEOVIA, EXALEAD, 3D VIA, BIOVIA, NETVIBES and 3DEXCITE are registered trademarks of Dassault Systèmes or its subsidiaries in the US and/or other countries.*

For more information on Dassault Systèmes' industry solution experiences for life sciences, visit <http://www.3ds.com/industries/life-sciences/>

### **About Ipsen**

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology (adult & pediatric). Ipsen's commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2015, R&D expenditure totaled close to €193 million. The Group has more than 4,600 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit [www.ipsen.com](http://www.ipsen.com).

### **Ipsen Forward Looking Statements**

The forward-looking statements, objectives and targets contained herein are based on the Group's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying



assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group's activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group's partners could generate lower revenues than expected. Such situations could have a negative impact on the Group's business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.

#### **For further information:**

##### **Media**

##### **Didier Véron**

Senior Vice-President, Public Affairs  
and Communication  
Tel.: +33 (0)1 58 33 51 16  
Fax: +33 (0)1 58 33 50 58  
E-mail: [didier.veron@ipsen.com](mailto:didier.veron@ipsen.com)

##### **Brigitte Le Guennec**

Corporate External Communication Manager  
Tel.: +33 (0)1 58 33 51 17  
Fax: +33 (0)1 58 33 50 58  
E-mail : [brigitte.le.guennec@ipsen.com](mailto:brigitte.le.guennec@ipsen.com)

##### **Financial Community**

##### **Stéphane Durant des Aulnois**

Vice-President, Investor Relations  
Tel.: +33 (0)1 58 33 60 09  
Fax: +33 (0)1 58 33 50 63  
E-mail: [stephane.durant.des.aulnois@ipsen.com](mailto:stephane.durant.des.aulnois@ipsen.com)

##### **Dassault Systèmes Press Contacts**

Corporate / France	Arnaud MALHERBE	<a href="mailto:arnaud.malherbe@3ds.com">arnaud.malherbe@3ds.com</a>	+33 (0)1 61 62 87 73
North America	Suzanne MORAN	<a href="mailto:suzanne.moran@3ds.com">suzanne.moran@3ds.com</a>	+1 (781) 810 3774
EMEAR	Virginie BLINDENBERG	<a href="mailto:virginie.blindenberg@3ds.com">virginie.blindenberg@3ds.com</a>	+33 (0) 1 61 62 84 21
China	Grace MU	<a href="mailto:grace.mu@3ds.com">grace.mu@3ds.com</a>	+86 10 6536 2288
Japan	Yukiko SATO	<a href="mailto:yukiko.sato@3ds.com">yukiko.sato@3ds.com</a>	+81 3 4321 3841
Korea	Myoungjoo CHOI	<a href="mailto:myoungjoo.choi@3ds.com">myoungjoo.choi@3ds.com</a>	+82 10 8947 6493
India	Seema SIDDIQUI	<a href="mailto:seema.siddiqui@3ds.com">seema.siddiqui@3ds.com</a>	+91 1244 577 100
AP South	Tricia SIM	<a href="mailto:tricia.sim@3ds.com">tricia.sim@3ds.com</a>	+65 6511 7954